Jubilant Pharma Limited Officer-Quality Control
Jubilant Pharma Limited is a global integrated pharmaceutical
company offering a wide range of products and services to its customers across
geographies. We organise our business into two segments, namely, Specialty Pharmaceuticals,
comprising Radiopharmaceuticals (including Radio pharmacies), Contract
Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy
Products, and Generics & APIs, comprising Solid Dosage Formulations &
Active Pharmaceutical Ingredients.
Jubilant Generics (JGL) is a wholly - owned subsidiary of
Jubilant Pharma. JGL in India has Research & Development units at Noida and
Mysore. It has two manufacturing facilities one at Mysore, Karnataka and
another at Roorkee, Uttarakhand, engaged in APIs and Dosage manufacturing,
respectively.
The manufacturing location at Mysore is spread over 69 acres
and it’s a USFDA approved site engaged in manufacturing of APIs, and caters to
the sales worldwide. API portfolio focusses on Lifestyle driven Therapeutic
Areas (CVS, CNS) and targets complex and newly approved molecules. The company
is the market leader in four APIs and is amongst the top three players for
another three APIs in its portfolio helping it maintain a high contribution
margin. The manufacturing location at Roorkee, Uttarakhand is state of the art
facility and is audited and approved by USFDA, Japan PMDA, UK MHRA, TGA, WHO
and Brazil ANVISA. This business focusses on B2B model for EU, Canada and
emerging markets.
Both manufacturing units are backward- integrated and are
supported by around 500 research and development professionals based at Noida
and Mysore. R&D works on Development of new products in API, Solid Dosage
Formulations of Oral Solid, Sterile Injectable, Semi-Solids Ointments, Creams
and Liquids. All BA/BE studies are done In house at our 80 Bed facility which
is inspected and having approvals /certifications from The Drugs Controller
General (India) and has global regulatory accreditations including USFDA, EMEA,
ANVISA (Brazil), INFRAMED (Portugal Authority), NPRA(Malaysia), AGES MEA
(Austria) for GCP and NABL, CAP accreditations for Path lab services.
JGL’s full-fledged Regulatory Affairs & IPR professionals
ensures unique portfolio of patents and product filings in regulatory and non-regulatory
market.
Revenue of Jubilant Pharma is constantly increasing and
during the Financial Year 2018 -19 it was INR 53,240 Million as compared to INR
39,950 Million during the Financial Year 2017-18.
Kindly refer www.jubilantpharma.com for more information
about organization.
TO APPLY CLICK HERE
No comments:
Post a Comment